John Ventre - Concepedia

Concepedia

Author

John Ventre

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

J Ventre, JOHN VENTRE, John R. Ventre, John Ventre

20

Publications

7.9K

Citations

15

H-Index

52

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)United States Military Academy New Frontier

JV

About

John Ventre is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, health sciences, and physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	1.6K
2	Health Sciences	7	7	1.3K
3	Biochemistry	6	6	1.3K
4	Cell Biology	3	3	927
5	Natural Sciences	1	1	321

John Ventre

×

16

Publications

7.9K

Citations

15

H-Index

	Year	Citations
Role of AMP-activated protein kinase in mechanism of metformin action Gaochao Zhou, Robert P. Myers, Ying Li, Journal of Clinical Investigation	2001	5.3K
Role of AMP-activated protein kinase in mechanism of metformin action Gaochao Zhou, Robert P. Myers, Ying Li, Journal of Clinical Investigation Metformin ActionCytoskeletonCellular PhysiologyMetabolic SyndromeSignaling Pathway	2001	632
Novel Peroxisome Proliferator-activated Receptor (PPAR) γ and PPARδ Ligands Produce Distinct Biological Effects Joel P. Berger, Mark D. Leibowitz, Thomas W. Doebber, Journal of Biological Chemistry	1999	411
Distinct Properties and Advantages of a Novel Peroxisome Proliferator-Activated Protein γ Selective Modulator Joel P. Berger, Ann Petro, Karen L. MacNaul, Molecular Endocrinology Lipid PeroxidationMolecular BiologyRedox BiologyOxidative StressMetabolic Syndrome	2003	321
Targeted Disruption of the Tumor Necrosis Factor-α Gene: Metabolic Consequences in Obese and Nonobese Mice John Ventre, Thomas W. Doebber, Margaret Wu, Diabetes Metabolic DisorderNonobese MicePathologyMetabolic RemodelingInsulin Signaling	1997	277
Peroxisome Proliferator-Activated Receptors γ and α Mediate in Vivo Regulation of Uncoupling Protein (UCP-1, UCP-2, UCP-3) Gene Expression Linda Kelly, Pasquale P. Vicario, G M Thompson, Endocrinology	1998	271
Low density lipoprotein is protected from oxidation and the progression of atherosclerosis is slowed in cholesterol-fed rabbits by the antioxidant N,N'-diphenyl-phenylenediamine. Carl P. Sparrow, Thomas W. Doebber, Jurek Olszewski, Journal of Clinical Investigation NutritionLipid PeroxidationHyperlipidemiaRedox BiologyOxidative Stress	1992	206
Role of Skeletal Muscle in Thiazolidinedione Insulin Sensitizer (PPARγ Agonist) Action Juleen R. Zierath, Jeffrey W. Ryder, Thomas W. Doebber, Endocrinology	1998	132
High fat fed hamster, a unique animal model for treatment of diabetic dyslipidemia with peroxisome proliferator activated receptor alpha selective agonists Pei-Ran Wang, Qiu Guo, Marc C. Ippolito, European Journal of Pharmacology Metabolic SyndromeBiochemistryMedicineUnique Animal ModelDiabetes	2001	59
Evidence for Peroxisome Proliferator-Activated Receptor (PPAR)α-Independent Peroxisome Proliferation: Effects of PPARγ/δ-Specific Agonists in PPARα-Null Mice John G. DeLuca, Thomas W. Doebber, Linda J Kelly, Molecular Pharmacology	2000	53

Page 1